Stada Arzneimittel AG - Company Profile
Powered by 
All the sales intelligence you need on Stada Arzneimittel AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Stada Arzneimittel AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Stada Arzneimittel AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Business Description
Stada Arzneimittel AG (Stada), a subsidiary of Nidda Healthcare GmbH, (Stada) is a manufacturer of consumer healthcare, generics, and specialty pharmaceutical products. The company has also established strategic partnerships and alliances with various organizations to enhance its capabilities and expand its product portfolio. It serves patients, doctors, pharmacies, hospitals, wholesalers, and other service providers in the health care market, public health insurance organizations, or private insurance companies. The company offers its product through a network of sales offices, alliance partners, distributors, and retail stores in over 100 countries globally.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company conducts R&D to focus on the development of innovative products related to neurology and nephrology, such as advanced parkinson’s disease, multiple sclerosis, and immunoglobulin A nephropathy (IgAN). As of December 2024, the company is currently focused on the introduction of seven biosimilar and four innovative treatments. Its R&D efforts also focus on expanding generics and branded product business and strive for additional growth opportunities, including non-regulated markets and niche markets, driven by innovative products. In FY2024, it spent EUR107 million on R&D, which as a percentage of revenue, stood at 2.6% and grew 10% YoY. As of December 2024, the company had more than 260 projects, including 150 internal product developments in seven development centers spread across six countries.
Business Segments
Overview
Offers non-prescription products, such as over-the-counter medicines, medical devices, cosmeceuticals and cosmetics, vitamins, minerals, supplements, and certain consumer products such as household disinfectants. Consumer health categories include cough and cold; derma; pain and relief; gastro; vitamins, minerals, supplements; and other CHC. Sold through healthcare experts such as pharmacists or doctors. Brands include Grippostad, Nizoral, Zoflora, Snup, Silomat, Hirudoid, Covonia, and Venoruton, among others.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Conducts business through three sub-segments: specialty generics (including branded generics), biosimilars, and innovative specialty pharmaceuticals. Specialty generics (including branded generics) offer branded generic products and specialty generics such as prescription drugs for chronic or complex or rare, or genetic conditions. Therapy areas include multiple myeloma, chronic myelogenous and acute lymphoblastic leukemia, prostate cancer, breast cancer, anti-HIV-1, diabetes, cardiovascular/hypertension, and pain disorders. Biosimilars offer products such as insulin, growth hormones, or monoclonal antibodies. Innovative Specialty Pharmaceuticals includes niche and orphan drugs. Brands include SILAPO, APO-go, Oyavas, Movymia, Lecigon, Hukyndra, Versatis, Ocrevus, and Kinpeygo, among others.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers prescription drugs sold under their International Non-Proprietary Name (INN). It also offers certain other products, such as CMO sales of APIs or wholesale goods sold by certain affiliates. Therapy areas include nervous system and pain; cardiovascular; alimentary tract and metabolism; antiinfectives; urology and sex hormones; musculoskeletal system; and respiratory system. Sold through pharmacies and hospitals. Brands include Tilidine, Amoxi-Clavulane, Atorvastatin, Pantoprazole, Ezetimibe, Ezetimibe, Olmesartan, Candesartan, Bisoprolol, and Rosuvastatin, among others.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer